Larimar Therapeutics, Inc. (LRMR) Tops Q1 EPS by 22c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q1 EPS of ($0.31), $0.22 better than the analyst estimate of ($0.53).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Ticketplus files for IPO with shares priced between $13-$15